Candel Therapeutics (CADL) Cash from Operations (2020 - 2025)
Candel Therapeutics (CADL) posted Cash from Operations of 10568000.0 for Q4 2025, down 3.24% sequentially from 10236000.0 in Q3 2025, and down 81.77% YoY from 57964483.02 in Q4 2024.
Candel Therapeutics (CADL) Cash from Operations (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Cash from Operations for 6 years, with the latest figure at 10568000.0 in Q4 2025.
- Quarterly Cash from Operations fell 81.77% year-over-year to 10568000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 38311000.0 (down 41.77% YoY) and the FY2025 annual result came in at 38311000.0, down 41.77% from the prior year.
- Cash from Operations retreated to 10568000.0 in Q4 2025 per CADL's latest filing, from 10236000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 4459000.0 in Q2 2021 and troughed at 10819000.0 in Q1 2023.
- A 5-year average of 7660750.0 and a median of 7308500.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2021 and 2024: Cash from Operations plunged 358.07% in 2021, then advanced 25.37% in 2024.
- Over 5 years, Cash from Operations stood at 5238000.0 in 2021, then slumped by 31.44% to 6885000.0 in 2022, then slipped by 7.8% to 7422000.0 in 2023, then rose by 21.67% to 5814000.0 in 2024, then plunged by 81.77% to 10568000.0 in 2025.
- According to Business Quant data, Cash from Operations over the past three periods registered 10568000.0, 10236000.0, and 8891000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | -10.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.57 Mn |
| Dec 31, 2025 | -10.57 Mn |
| Sep 30, 2025 | -10.24 Mn |
| Sep 30, 2025 | -10.24 Mn |
| Jun 30, 2025 | -8.89 Mn |
| Jun 30, 2025 | -8.89 Mn |
| Mar 31, 2025 | -8.62 Mn |
| Mar 31, 2025 | -8.62 Mn |
| Dec 31, 2024 | -5.81 Mn |
| Dec 31, 2024 | -5.81 Mn |
| Sep 30, 2024 | -6.57 Mn |
| Sep 30, 2024 | -6.57 Mn |
| Jun 30, 2024 | -6.20 Mn |
| Jun 30, 2024 | -6.20 Mn |
| Mar 31, 2024 | -8.44 Mn |
| Mar 31, 2024 | -8.44 Mn |
| Dec 31, 2023 | -7.42 Mn |
| Dec 31, 2023 | -7.42 Mn |
| Sep 30, 2023 | -8.81 Mn |
| Sep 30, 2023 | -8.81 Mn |